4.7 Article

Associations of Warfarin Use with Risks of Ischemic Cerebrovascular Events and Major Bleeding in Patients with Hyperthyroidism-Related Atrial Fibrillation

期刊

BIOMEDICINES
卷 10, 期 11, 页码 -

出版社

MDPI
DOI: 10.3390/biomedicines10112670

关键词

atrial fibrillation; hyperthyroidism; warfarin; ischemic stroke; transient ischemic attack

资金

  1. New Taipei Municipal TuCheng Hospital [CFRPVVL0011]
  2. Ministry of Science and Technology of Taiwan [MOST 110-2511-H-038-005]
  3. Taipei Medical University Hospital [111TMUH-MOST-07]

向作者/读者索取更多资源

The use of warfarin therapy in patients with new-onset hyperthyroidism-related atrial fibrillation did not show a significant benefit in terms of the risk of ischemic stroke/transient ischemic attack or major bleeding. Warfarin use also did not have a significant association with the risk of stroke/TIA compared to aspirin use.
The use of oral anticoagulants for patients with new-onset hyperthyroidism-related atrial fibrillation (AF) is controversial. We aimed to evaluate the clinical benefits of warfarin therapy in this population. This retrospective cohort study used a data-cut of Taiwan Health and Welfare Database between 2000 and 2016. We compared warfarin users and nonusers among AF patients with hyperthyroidism. We used 1:2 propensity score matching to balance covariates and Cox regression model to calculate hazard ratios (HRs). The primary outcome was risk of ischemic stroke/transient ischemic attack (TIA), and the secondary outcome was major bleeding. After propensity score matching, we defined 90 and 168 hyperthyroidism-related AF patients with mean (SD) age of 59.9 +/- 13.5 and 59.2 +/- 14.6 in the warfarin-treated group and untreated group separately. The mean (SD) CHA2DS2-VASc scores for the two groups were 2.1 +/- 1.6 and 1.8 +/- 1.5, respectively. Patients with hyperthyroidism-related AF receiving warfarin had no significant risk of ischemic stroke/TIA (adjusted HR: 1.16, 95% confidence interval [CI]: 0.52-2.56, p = 0.717) compared to nonusers. There was a comparable risk of major bleeding between those receiving warfarin or not (adjusted HR: 0.91, 95% CI: 0.56-1.47, p = 0.702). The active-comparator design also demonstrated that warfarin use had no significant association with the risk of stroke/TIA versus aspirin use (adjusted HR: 2.43; 95% CI: 0.68-8.70). In conclusion, anticoagulation therapy did not have a statistically significant benefit on ischemic stroke/TIA nor risk of bleeding, among patients with new-onset hyperthyroidism-related AF under a low CHA2DS2-VASc score, by comparing those without use.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据